Manipulating the Peri-Infarct Area Using Maraviroc to Enhance Motor Skills After Stroke
Recruiting
Phase 2
Interventional Study
Ischemic Stroke
Stroke
Stroke Acute
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 80 (estimated)
- Sponsor
- Emmanuel Carrera · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
MASTER is a single-center, patient and investigator-blinded, Randomized Controlled Trial (RCT) to compare the efficacy of Maraviroc, a C-C chemokine receptor 5 (CCR5) antagonist, against placebo regarding motor function and motor learning skills in the first 3 months after ischemic stroke.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Informed consent as documented by signature
* ≥18 years at time of signing of informed consent
* Acute ischemic stroke.
* Stroke onset \< 7 days from randomization.
* Contralateral, unilateral, incomplete upper limb paresis, incl. :
* FMA-UE \< 63/66
* Residual voluntary finge…
Contacts